A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02797964|
Recruitment Status : Completed
First Posted : June 14, 2016
Results First Posted : March 10, 2022
Last Update Posted : March 10, 2022
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)||Drug: SRA737||Phase 1 Phase 2|
SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1, a key regulator of cell cycle progression and the DNA Damage Response (DDR) replication stress response. In cancer cells, intrinsic replication stress (RS) is induced by factors such as oncogenes (e.g., CCNE1 or MYC), genetic mutations in DNA repair machinery (e.g. BRCA1 or FANCA), genetic mutations leading to a dysregulated cell cycle (e.g., TP53 or RAD50) or other genomic alterations. This replication stress results in persistent DNA damage and genomic instability, leading to an increased dependency on Chk1 for survival. Targeted inhibition of Chk1 by SRA737 may therefore be synthetically lethal to cancer cells with elevated intrinsic RS.
This study has been designed to: establish the safety profile; determine the pharmacokinetic profile; identify the optimal dose, schedule, and MTD; obtain preliminary evidence of activity; and evaluate SRA737's efficacy in prospectively-selected subjects with tumors that harbor genomic alterations linked to increased replication stress and that are hypothesized to be more sensitive to Chk1 inhibition via synthetic lethality.
This clinical study consists of two phases, a Dose Escalation Phase 1 portion and a Cohort Expansion Phase 2 portion.
In the Dose Escalation Phase 1 portion, cohorts consisting initially of a single subject will receive escalating doses of SRA737, administered orally on a continuous daily dosing schedule in 28-day cycles. Once an SRA737-related Grade 2 toxicity is observed in a dose escalation cohort during Cycle 1, that cohort will be expanded to 3 to 6 subjects, and subsequent dose level cohorts will follow a rolling 6 design until the MTD has been identified.
In the Cohort Expansion Phase 2 portion, subjects with genetically-defined tumors that harbor genomic alterations linked to increased replication stress and that are hypothesized to be more sensitive to Chk1 inhibition will be prospectively enrolled into six indication-specific cohorts to explore the preliminary efficacy of SRA737. Subjects must have advanced or metastatic disease of one of the following types:
- castration-resistant prostate cancer (mCRPC);
- high grade serous ovarian cancer (HGSOC) without CCNE1 gene amplification;
- HGSOC with CCNE1 gene amplification (or alternative genetic alteration with similar functional effect);
- non-small cell lung cancer (NSCLC);
- head and neck squamous cell carcinoma (HNSCC) or squamous cell carcinoma of the anus (SCCA); and
- colorectal cancer (mCRC).
To qualify for enrolment in the Cohort Expansion Phase 2 portion, the subject's tumor must have a confirmed combination of mutations which are expected to confer sensitivity to Chk1 inhibition, determined by the Sponsor's review of genetic abnormalities detected in the following categories:
- Oncogenic drivers such as CCNE1 or MYC, etc.
- Genes involved in the DNA repair process including BRCA1, BRCA2, FANC genes, mismatch repair (MMR) genetic alterations and/or high microsatellite instability.
- Key tumor suppressor genes regulating G1 cell cycle progression/arrest such as TP53, RAD50, etc. For patients with HNSCC or SCCA, positive human papilloma virus (HPV) status is also considered for eligibility.
- Genetic indicators of replicative stress such as gain of function/amplification of CHEK1, ATR or other related genes.
Tumor genetics will be prospectively determined using Next-Generation Sequencing.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||107 participants|
|Intervention Model:||Sequential Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer|
|Actual Study Start Date :||July 2016|
|Actual Primary Completion Date :||October 28, 2019|
|Actual Study Completion Date :||October 28, 2019|
|Experimental: Open label||
SRA737 will be administered orally on each day of a 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Subjects can continue taking SRA737 if they are receiving clinical benefit and able to safely take the drug and follow the requirements of the study.
- Number of Subjects With Adverse Events as Assessed by CTCAE 4.03 [ Time Frame: Up to 30 days after last dose of SRA737 ]Treatment-emergent adverse events (TEAEs) were reported until the safety Follow up (SFU) visit, 30 days after the last dose of SRA737 or prior to the initiation of a new anticancer treatment, whichever came first.
- Maximum Tolerated Dose of SRA737 [ Time Frame: Cycle 1 (28 days) in the Dose Escalation Phase ]The highest dose at which ≤ 33% of subjects have a dose limiting toxicity (DLT) in a cohort of up to 6 subjects.
- Recommended Phase 2 Dose of SRA737 [ Time Frame: Up to 30 days after last dose of SRA737 ]The RP2D and schedule were defined by the Cohort Review Committee at the end of the study and took all clinically relevant toxicity, PK and PDn data into account. The RP2D was to be a dose equal to or less than the MTD for the selected schedule.
- Disease Control Rate (DCR) of SRA737 [ Time Frame: Radiographic tumor assessments were performed every 2 cycles of therapy. ]The disease control rate (DCR) was defined as the number of subjects achieving complete response (CR) + partial response (PR) + stable disease (SD) per RECIST 1.1 criteria. Since no subjects achieved CR or PR in this study, the DCR represents the proportion of subjects in each group who achieved SD.
- Time to Progression (TTP) [ Time Frame: Radiographic tumor assessments were performed every 2 cycles of therapy. Follow-up assessments were made every 16 weeks for subjects who had not progressed and had not initiated new anticancer therapy. ]Time to progression (TTP) was defined as the time from Cycle 1 Day 1 to the earliest date of radiographic disease progression per RECIST 1.1, or if the subject did not experience disease progression, to the last imaging assessment. TTP was analyzed using the K-M method.
- Progression Free Survival (PFS) [ Time Frame: Radiographic tumor assessments were performed every 2 cycles of therapy. Follow-up assessments were made every 16 weeks for subjects who had not progressed and had not initiated new anticancer therapy. ]Progression free survival (PFS) was defined as time from Cycle 1 Day 1 to the earliest date of radiographic disease progression per RECIST 1.1 or death, whichever happened first. Censoring rules are defined in the SAP. PFS was analyzed using the K-M method.
- Overall Survival (OS) [ Time Frame: Follow-up assessments were made every 16 weeks for subjects who had not progressed and had not initiated new anticancer therapy. ]Overall survival (OS) was defined as time from Cycle 1 Day 1 to the date of death (or date last known to be alive). OS was analyzed using the K-M method.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
Key Inclusion Criteria:
- For Dose Escalation Only: any locally advanced or metastatic, histologically or cytologically proven solid tumor or NHL, relapsed after or progressing despite conventional treatment
- Life expectancy of at least 12 weeks
- World Health Organization (WHO) performance status of 0-1
- Must meet select hematological and biochemical laboratory indices
- Archival tumor tissue or accessible tumor and willingness to consent to a biopsy
Any locally advanced or metastatic malignancy of the following types for which no other conventional therapy is considered appropriate:
- Metastatic Colorectal Cancer (CRC)
- Platinum-resistant or intolerant High Grade Serious Ovarian Cancer (HGSOC)
- Advanced Non-Small Cell Lung Cancer (NSCLC)
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Head and Neck Squamous Cell Carcinoma (HNSCC) or squamous cell carcinoma of the anus (SCCA).
- Eligibility may be further restricted by the select number of prior regimens specific to each indication
Measurable disease per RECIST v1.1, or for mCRPC, evaluable disease per any of the following:
- Measurable disease per RECIST v1.1
- Increasing PSA
- Circulating tumor cell (CTC) count of 5 or more cells per 7.5 ml of blood
Tumor tissue or ctDNA evidence that subject's tumor harbors a combination of mutations which are expected to confer sensitivity to Chk1 inhibition. Eligibility will be determined by the Sponsor's review of genetic abnormalities detected in genes in the following categories:
- Oncogenic drivers such as MYC, CCNE1, etc.
- Key tumor suppressor genes regulating G1 cell cycle progression/arrest such as RAD50, TP53, etc. For patients with NHSCC or SCCA, positive HPV status is also considered for eligibility.
- The DDR pathway including BRCA1, BRCA2 and FANC. For patients with CRC, MMR genetic alterations and/or high microsatellite instability are also considered for eligibility.
- Genetic indicators of replicative stress such as gain of function/amplification of Chk1 or ATR or other related gene.
Key Exclusion Criteria:
Received the following prior or current anticancer therapy:
- Radiotherapy within the last 6 weeks
- Endocrine therapy during the previous 4 weeks
- Chemotherapy during the previous 4 weeks
- Immunotherapy during the previous 6 weeks
- Nitrosoureas or Mitomycin C during the previous 6 weeks
- Other Investigational Medicinal Product during the 4 weeks before treatment
- Any prior treatment with a Chk1 inhibitor or prior treatment with an ATR inhibitor within 6 months prior to receiving SRA737
- Other malignancy within the past 2 years, except for adequately treated tumors
- Ongoing toxic manifestations of previous treatments greater than NCI-CTCAE Grade 1
- For Dose Escalation: new or progressing brain metastases. For Cohort Expansion: present or prior brain metastases
- High medical risk because of nonmalignant systemic disease
- Serologically positive for hepatitis B, hepatitis C or HIV
- Serious cardiac condition, left ventricular ejection fraction < 45% at baseline, history of cardiac ischemia within the past 6 months, or prior history of cardiac arrhythmia requiring treatment
- Prior bone marrow transplant or extensive radiotherapy to greater than 25% of bone marrow within 8 weeks
- Peanut allergy
- QTcF> 450 msec in adult males and > 470 msec in adult females
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of SRA737
- Inability to swallow capsules without chewing or crushing
- Is a participant or plans to participate in another interventional clinical trial
- Any other condition which in the Investigator's opinion would not make the subject a good candidate
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02797964
|Royal Marsden Hospital|
|Sutton, London, United Kingdom, SM2 5PT|
|Belfast City Hospital|
|Belfast, Northern Ireland, United Kingdom, BT9 7AB|
|Oxford University Hospitals|
|Headington, Oxford, United Kingdom, OX3 7LE|
|Velindre Cancer Centre - Cardiff|
|Cardiff, Whitchurch, United Kingdom, CF14 2TL|
|The Clatterbridge Cancer Centre|
|Bebington, Wirral, United Kingdom, CH63 4JY|
|Western General Hospital|
|Edinburgh, United Kingdom, EH4 2XU|
|The Beatson West of Scotland Cancer Centre|
|Glasgow, United Kingdom, G12 0YN|
|The Leeds Teaching Hospitals of St James University Hospital|
|Leeds, United Kingdom, LS9 7TF|
|University Hospitals of Leicester|
|Leicester, United Kingdom, LE1 5WW|
|Guy's and St. Thomas|
|London, United Kingdom, SE1 9RT|
|Sarah Cannon Research Institute|
|London, United Kingdom, W1G 6AD|
|University College London Hospitals|
|London, United Kingdom, W1T 7HA|
|Manchester, United Kingdom, M20 4BX|
|Newcastle upon Tyne, United Kingdom, NE7 7DN|
|Sheffield Teaching Hospitals|
|Sheffield, United Kingdom, S10 2SJ|
Documents provided by Sierra Oncology, Inc.:
|Responsible Party:||Sierra Oncology, Inc.|
|Other Study ID Numbers:||
|First Posted:||June 14, 2016 Key Record Dates|
|Results First Posted:||March 10, 2022|
|Last Update Posted:||March 10, 2022|
|Last Verified:||March 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
Advanced solid tumors
Metastatic Colorectal Cancer
Platinum-Resistant or Intolerant High Grade Serious Ovarian Cancer
Advanced Non-Small Cell Lung Cancer
Metastatic Castration-Resistant Prostate Cancer
Head and Neck Squamous Cell Carcinoma
Squamous Cell Carcinoma of the Anus
Checkpoint kinase 1
Neoplasms by Histologic Type
Immune System Diseases